Literature DB >> 8694663

Prevalence of hypercholesterolemia among siblings of persons with premature coronary heart disease. Application of the Second Adult Treatment Panel guidelines.

J K Allen1, D R Young, R S Blumenthal, T F Moy, L R Yanek, L Wilder, L C Becker, D M Becker.   

Abstract

BACKGROUND: Increased blood cholesterol, specifically high low-density lipoprotein cholesterol, increases risk for coronary heart disease (CHD). Persons with a positive family history of premature CHD also are at markedly increased risk.
OBJECTIVE: To examine the prevalence of hypercholesterolemia based on the second report of the National Cholesterol Educational Program Adult Treatment Panel (ATP II) guidelines in the asymptomatic healthy siblings of people with premature CHD.
METHODS: A total of 668 asymptomatic healthy siblings (354 men and 314 women) underwent screening for risk factors for CHD. Siblings were categorized into treatment categories for primary prevention defined by ATP II. The percentage who were candidates for intervention were compared with the published national estimates for those without CHD from the third National Health and Nutrition Examination Survey (NHANES III).
RESULTS: Based on ATP II guidelines, 65% of the asymptomatic adult siblings required fasting lipoprotein analysis compared with 33% of adults without CHD in the national reference population. Of the siblings who met the criteria for fasting lipoprotein analysis, most (56%) were candidates for dietary therapy, more than twice the proportion of adults from NHANES III. The percentage of the siblings who qualified for drug intervention and dietary therapy was 3 times greater than the national sample, 33% vs 11%, respectively. Assuming a 10% hypothetical reduction in low-density lipoprotein cholesterol levels as the result of dietary modification, the proportion of the sibling sample who were possible candidates for drug therapy was 20%, still 4 times that predicted for the national sample.
CONCLUSIONS: These results underscore the need for aggressive detection and treatment of hypercholesterolemia in this easily identifiable high-risk population of siblings of people with premature CHD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694663

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

Review 1.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

Review 2.  Screening relatives of patients with premature coronary heart disease.

Authors:  Gilbert R Thompson
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

3.  Smoking influences the association between apolipoprotein E and lipids: the National Heart, Lung, and Blood Institute Family Heart Study.

Authors:  L Djoussé; R H Myers; H Coon; D K Arnett; M A Province; R C Ellison
Journal:  Lipids       Date:  2000-08       Impact factor: 1.880

4.  Motivational interviewing to support modifiable risk factor change in individuals at increased risk of cardiovascular disease: A systematic review and meta-analysis.

Authors:  Justin Lee Mifsud; Joseph Galea; Joanne Garside; John Stephenson; Felicity Astin
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

5.  Coronary risk reduction intervention for siblings and offspring of patients with premature coronary heart disease: the CRISO study protocol for a randomised controlled pilot study.

Authors:  Justin Lee Mifsud; John Stephenson; Felicity Astin; Joseph Galea
Journal:  Pilot Feasibility Stud       Date:  2021-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.